Efficacy and Safety of Obinutuzumab in Immune-Mediated Thrombotic Thrombocytopenic Purpura.
作者信息
Weisinger Julia, Bouzid Raïda, Fadlallah Jehane, Barbet Christelle, Provot Francois, Poullin Pascale, Neel Antoine, Marie Manon, Rieu Virginie, Kanouni Tarik, Moranne Olivier, Azoulay Elie, Marjanovic Zora, Corre Elise, Joly Anne-Christine, Baylatry Minh-Tam, Joly Bérangère S, Veyradier Agnes, Coppo Paul
机构信息
Centre de Référence Des Microangiopathies Thrombotiques, Service d'hématologie, Hôpital Saint Antoine, Assistance Publique-Hôpitaux de Paris, Sorbonne Université, Paris, France.
INSERM Unité Mixte de Recherche (UMRS) 1138, Centre de Recherche des Cordeliers, Université Paris Cité, Sorbonne Université, Paris, France.
出版信息
Am J Hematol. 2025 Feb;100(2):350-353. doi: 10.1002/ajh.27550. Epub 2024 Dec 12.
Abstract
摘要
相似文献
1
Efficacy and Safety of Obinutuzumab in Immune-Mediated Thrombotic Thrombocytopenic Purpura.奥妥珠单抗治疗免疫性血栓性血小板减少性紫癜的疗效与安全性
Am J Hematol. 2025 Feb;100(2):350-353. doi: 10.1002/ajh.27550. Epub 2024 Dec 12.
2
[Immune thrombotic thrombocytopenic purpura treated with Obinutuzumab: a case report and literature review].[用奥滨尤妥珠单抗治疗免疫性血栓性血小板减少性紫癜：1例病例报告及文献综述]
Zhonghua Xue Ye Xue Za Zhi. 2024 Dec 30;45(S1):53-56. doi: 10.3760/cma.j.cn121090-20241123-00474.
3
The use of obinutuzumab and ofatumumab in the treatment of immune thrombotic thrombocytopenic purpura.奥滨尤妥珠单抗和奥法妥珠单抗在免疫性血栓性血小板减少性紫癜治疗中的应用。
Br J Haematol. 2022 Jul;198(2):391-396. doi: 10.1111/bjh.18192. Epub 2022 Apr 17.
4
Anti-CD20 therapeutic options in immune-mediated thrombotic thrombocytopenic purpura.免疫介导性血栓性血小板减少性紫癜的抗 CD20 治疗选择。
Br J Haematol. 2022 Jul;198(2):225-226. doi: 10.1111/bjh.18215. Epub 2022 Apr 26.
5
A case of severe ADAMTS13 deficiency presenting as thrombotic thrombocytopenic purpura in pregnancy.一例以妊娠期血栓性血小板减少性紫癜为表现的严重ADAMTS13缺乏症病例。
Med Pregl. 2012 Sep-Oct;65(9-10):436-9. doi: 10.2298/mpns1210436n.
6
Efficacy and safety of daratumumab in multiresistant immune-mediated thrombotic thrombocytopenic purpura.达雷妥尤单抗治疗多重耐药免疫介导的血栓性血小板减少性紫癜的疗效和安全性。
Br J Haematol. 2024 Nov;205(5):1951-1958. doi: 10.1111/bjh.19752. Epub 2024 Sep 4.
7
Current management of thrombotic thrombocytopenic purpura.血栓性血小板减少性紫癜的当前管理
Curr Opin Hematol. 2008 Sep;15(5):445-50. doi: 10.1097/MOH.0b013e328309ec62.
8
ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission.ADAMTS13和抗ADAMTS13抗体作为获得性血栓性血小板减少性紫癜缓解期复发的标志物。
Haematologica. 2008 Feb;93(2):232-9. doi: 10.3324/haematol.11739. Epub 2008 Jan 26.
9
Inherited thrombotic thrombocytopenic purpura mimicking immune thrombocytopenic purpura during pregnancy: a case report.孕期表现为免疫性血小板减少性紫癜的遗传性血栓性血小板减少性紫癜：一例报告
J Med Case Rep. 2018 Jan 22;12(1):15. doi: 10.1186/s13256-017-1545-3.
10
Acquired Thrombotic Thrombocytopenic Purpura Without Anti-ADAMTS13 Antibody Caused by Influenza A (H1N1) Virus Successfully Treated by Plasma Exchange: A Case Report.获得性血栓性血小板减少性紫癜无抗 ADAMTS13 抗体由甲型流感病毒 (H1N1) 成功治疗血浆置换：一例报告。
Am J Case Rep. 2021 Aug 2;22:e932251. doi: 10.12659/AJCR.932251.
引用本文的文献
1
Early caplacizumab and obinutuzumab enable successful treatment of relapsing thrombotic thrombocytopenic purpura without therapeutic plasma exchange: a case report.早期使用卡帕西珠单抗和奥滨尤妥珠单抗可在不进行治疗性血浆置换的情况下成功治疗复发性血栓性血小板减少性紫癜：一例报告
Front Immunol. 2025 Apr 28;16:1588471. doi: 10.3389/fimmu.2025.1588471. eCollection 2025.
2
How we manage immune-mediated thrombotic thrombocytopenic purpura after rituximab failure or intolerance.利妥昔单抗治疗失败或不耐受后，我们如何管理免疫介导的血栓性血小板减少性紫癜。
Br J Haematol. 2025 Jun;206(6):1560-1570. doi: 10.1111/bjh.20101. Epub 2025 Apr 24.
本文引用的文献
1
The use of obinutuzumab and ofatumumab in the treatment of immune thrombotic thrombocytopenic purpura.奥滨尤妥珠单抗和奥法妥珠单抗在免疫性血栓性血小板减少性紫癜治疗中的应用。
Br J Haematol. 2022 Jul;198(2):391-396. doi: 10.1111/bjh.18192. Epub 2022 Apr 17.
2
Redefining outcomes in immune TTP: an international working group consensus report.重新定义免疫性血栓性血小板减少性紫癜的结局：国际工作组共识报告。
Blood. 2021 Apr 8;137(14):1855-1861. doi: 10.1182/blood.2020009150.
3
A regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP.卡泊单抗、免疫抑制和血浆置换联合治疗方案可预防免疫介导的血栓性血小板减少性紫癜的不良结局。
Blood. 2021 Feb 11;137(6):733-742. doi: 10.1182/blood.2020008021.
4
ISTH guidelines for treatment of thrombotic thrombocytopenic purpura.国际血栓与止血学会（ISTH）血栓性血小板减少性紫癜治疗指南。
J Thromb Haemost. 2020 Oct;18(10):2496-2502. doi: 10.1111/jth.15010. Epub 2020 Sep 11.
5
Thrombotic thrombocytopenic purpura.血栓性血小板减少性紫癜。
Blood. 2017 May 25;129(21):2836-2846. doi: 10.1182/blood-2016-10-709857. Epub 2017 Apr 17.
6
Preemptive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpura.在缓解后进行预防性利妥昔单抗输注可有效预防获得性血栓性血小板减少性紫癜的复发。
Blood. 2014 Jul 10;124(2):204-10. doi: 10.1182/blood-2014-01-550244. Epub 2014 May 28.
Zotero 插件